Alimera Sciences Stock
Your prediction
Pros and Cons of Alimera Sciences in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 0.970% | 0.000% | -8.108% | -3.774% | -5.556% | -38.554% | -56.034% |
| Corcept Therapeutics Inc. | 1.470% | 4.607% | 28.790% | 69.184% | 49.093% | 256.469% | 482.571% |
| Supernus Pharmaceuticals | -0.480% | 1.449% | 0.000% | 16.022% | -2.326% | 51.079% | 107.921% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat